Susan G Kornstein

Summary

Affiliation: Virginia Commonwealth University
Country: USA

Publications

  1. ncbi request reprint Desvenlafaxine for the treatment of major depressive disorder
    Susan G Kornstein
    Department of Psychiatry and Institute for Women s Health, Virginia Commonwealth University, PO Box 980319, Richmond, VA 23298 0319, USA 1 804 827 1200 1 804 827 0957
    Expert Opin Pharmacother 15:1449-63. 2014
  2. ncbi request reprint Influence of sex and menopausal status on response, remission, and recurrence in patients with recurrent major depressive disorder treated with venlafaxine extended release or fluoxetine: analysis of data from the PREVENT study
    Susan G Kornstein
    Department of Psychiatry and Obstetrics Gynecology, Executive Director, Institute for Women s Health, PO Box 980319, Richmond, VA 23298
    J Clin Psychiatry 75:62-8. 2014
  3. pmc Do menopausal status and use of hormone therapy affect antidepressant treatment response? Findings from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study
    Susan G Kornstein
    Department of Psychiatry and Institute for Women s Health, Virginia Commonwealth University, Richmond, VA 23298 0710, USA
    J Womens Health (Larchmt) 22:121-31. 2013
  4. ncbi request reprint Analysis of depressive symptoms in patients with major depressive disorder treated with desvenlafaxine or placebo
    Susan G Kornstein
    Institute for Women s Health, Virginia Commonwealth University, Richmond, VA, USA
    Psychopharmacol Bull 42:21-35. 2009
  5. ncbi request reprint Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial
    Susan G Kornstein
    Department of Psychiatry, Virginia Commonwealth University, Richmond, USA
    J Clin Psychiatry 67:1767-75. 2006
  6. ncbi request reprint Beyond remission: rationale and design of the Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study
    Susan G Kornstein
    Department of Psychiatry, Virginia Commonwealth University School of Medicine, Richmond, VA 23298 0710, USA
    CNS Spectr 11:28-34. 2006
  7. pmc The influence of menopause status and postmenopausal use of hormone therapy on presentation of major depression in women
    Susan G Kornstein
    Department of Psychiatry and Institute for Women s Health, Virginia Commonwealth University, Richmond, VA, USA
    Menopause 17:828-39. 2010
  8. ncbi request reprint Escitalopram versus SNRI antidepressants in the acute treatment of major depressive disorder: integrative analysis of four double-blind, randomized clinical trials
    Susan G Kornstein
    Department of Psychiatry, Virginia Commonwealth University, Richmond, VA 23298 0710, USA
    CNS Spectr 14:326-33. 2009
  9. ncbi request reprint Analysis by age and sex of efficacy data from placebo-controlled trials of desvenlafaxine in outpatients with major depressive disorder
    Susan G Kornstein
    Department of Psychiatry and Institute for Women s Health, Virginia Commonwealth University, Richmond 23298 0710, USA
    J Clin Psychopharmacol 30:294-9. 2010
  10. ncbi request reprint Maintenance therapy to prevent recurrence of depression: summary and implications of the PREVENT study
    Susan G Kornstein
    Mood Disorders Institute, Institute for Women s Health, Department of Psychiatry, Virginia Commonwealth University, PO Box 980710, Richmond, VA 23298, USA
    Expert Rev Neurother 8:737-42. 2008

Detail Information

Publications53

  1. ncbi request reprint Desvenlafaxine for the treatment of major depressive disorder
    Susan G Kornstein
    Department of Psychiatry and Institute for Women s Health, Virginia Commonwealth University, PO Box 980319, Richmond, VA 23298 0319, USA 1 804 827 1200 1 804 827 0957
    Expert Opin Pharmacother 15:1449-63. 2014
    ..g., selective serotonin reuptake inhibitors), the majority of individuals with MDD do not achieve and sustain a recovered state. A substantial percentage of MDD patients require a treatment change due to poor efficacy or tolerability...
  2. ncbi request reprint Influence of sex and menopausal status on response, remission, and recurrence in patients with recurrent major depressive disorder treated with venlafaxine extended release or fluoxetine: analysis of data from the PREVENT study
    Susan G Kornstein
    Department of Psychiatry and Obstetrics Gynecology, Executive Director, Institute for Women s Health, PO Box 980319, Richmond, VA 23298
    J Clin Psychiatry 75:62-8. 2014
    ..To evaluate the effects of sex and menopausal status on acute-, continuation-, and maintenance-phase treatment outcomes in patients with recurrent major depressive disorder (MDD)...
  3. pmc Do menopausal status and use of hormone therapy affect antidepressant treatment response? Findings from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study
    Susan G Kornstein
    Department of Psychiatry and Institute for Women s Health, Virginia Commonwealth University, Richmond, VA 23298 0710, USA
    J Womens Health (Larchmt) 22:121-31. 2013
    ..This report evaluates whether menopausal status and use of hormonal contraceptives or menopausal HT affect outcome in women treated with citalopram...
  4. ncbi request reprint Analysis of depressive symptoms in patients with major depressive disorder treated with desvenlafaxine or placebo
    Susan G Kornstein
    Institute for Women s Health, Virginia Commonwealth University, Richmond, VA, USA
    Psychopharmacol Bull 42:21-35. 2009
    ..The aim of this study was to evaluate the impact of desvenlafaxine on a broad range of major depressive disorder (MDD) symptoms...
  5. ncbi request reprint Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial
    Susan G Kornstein
    Department of Psychiatry, Virginia Commonwealth University, Richmond, USA
    J Clin Psychiatry 67:1767-75. 2006
    ..The current trial examined the efficacy of maintenance escitalopram treatment in preventing depression recurrence in patients who responded to acute SSRI therapy...
  6. ncbi request reprint Beyond remission: rationale and design of the Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study
    Susan G Kornstein
    Department of Psychiatry, Virginia Commonwealth University School of Medicine, Richmond, VA 23298 0710, USA
    CNS Spectr 11:28-34. 2006
    ....
  7. pmc The influence of menopause status and postmenopausal use of hormone therapy on presentation of major depression in women
    Susan G Kornstein
    Department of Psychiatry and Institute for Women s Health, Virginia Commonwealth University, Richmond, VA, USA
    Menopause 17:828-39. 2010
    ..This study also evaluated these differences between postmenopausal women with major depressive disorder who are taking and not taking hormone therapy...
  8. ncbi request reprint Escitalopram versus SNRI antidepressants in the acute treatment of major depressive disorder: integrative analysis of four double-blind, randomized clinical trials
    Susan G Kornstein
    Department of Psychiatry, Virginia Commonwealth University, Richmond, VA 23298 0710, USA
    CNS Spectr 14:326-33. 2009
    ..Recent data suggest that escitalopram may be more effective in severe depression than other selective serotonin reuptake inhibitors...
  9. ncbi request reprint Analysis by age and sex of efficacy data from placebo-controlled trials of desvenlafaxine in outpatients with major depressive disorder
    Susan G Kornstein
    Department of Psychiatry and Institute for Women s Health, Virginia Commonwealth University, Richmond 23298 0710, USA
    J Clin Psychopharmacol 30:294-9. 2010
    ..006), 55-to-64 (P = 0.01), and 65-and-older (P = 0.02) subgroups among women but not in any age subgroup among men. Desvenlafaxine generally improved depressive symptoms across age and sex subgroups...
  10. ncbi request reprint Maintenance therapy to prevent recurrence of depression: summary and implications of the PREVENT study
    Susan G Kornstein
    Mood Disorders Institute, Institute for Women s Health, Department of Psychiatry, Virginia Commonwealth University, PO Box 980710, Richmond, VA 23298, USA
    Expert Rev Neurother 8:737-42. 2008
    ..The PREVENT study adds to current understanding regarding the benefits of long-term antidepressant therapy in preventing recurrence...
  11. pmc Assessing the efficacy of 2 years of maintenance treatment with venlafaxine extended release 75-225 mg/day in patients with recurrent major depression: a secondary analysis of data from the PREVENT study
    Susan G Kornstein
    Virginia Commonwealth University, Richmond, Virginia
    Int Clin Psychopharmacol 23:357-63. 2008
    ..007). Venlafaxine ER effectively maintained response at doses < or =225 mg/day for up to 2.5 years in patients with recurrent MDD. The findings are consistent with those of the full data set...
  12. doi request reprint Duloxetine in the treatment of generalized anxiety disorder
    Susan G Kornstein
    Department of Psychiatry, Virginia Commonwealth University, PO Box 980710, Richmond, VA 23298 0710, USA
    Expert Rev Neurother 9:155-65. 2009
    ..In all acute and long-term trials, duloxetine was well-tolerated. This body of research suggests that duloxetine should be one of the options considered as a first-line treatment for GAD...
  13. ncbi request reprint Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression
    Alan J Gelenberg
    Department of Psychiatry, Health Sciences Center, University of Arizona, PO Box 245002, Tucson, AZ 85724 5002, USA
    Biol Psychiatry 54:806-17. 2003
    ..This randomized, placebo-controlled study of the efficacy and safety of nefazodone in preventing recurrence was conducted for patients with chronic MDD...
  14. ncbi request reprint Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study
    James H Kocsis
    Department of Psychiatry, Weill Cornell Medical College, New York, NY 10012, USA
    J Clin Psychiatry 68:1014-23. 2007
    ..To test the long-term efficacy and safety of venlafaxine extended-release (ER) in preventing recurrence in patients with major depression...
  15. doi request reprint What predicts attrition in second step medication treatments for depression?: a STAR*D Report
    Diane Warden
    Department of Psychiatry, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390 9119, USA
    Int J Neuropsychopharmacol 12:459-73. 2009
    ..Focus on patients with attrition risk factors for medication augmentation or switch strategies may enhance retention and improve outcomes...
  16. ncbi request reprint Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, psychotherapy, and their combination
    John Zajecka
    Department of Psychiatry, Rush Presbyterian St Luke s Medical Center, 1725 W Harrison Street, Suite 955, Chicago, IL 60612, USA
    J Clin Psychiatry 63:709-16. 2002
    ..This study compares the effects of antidepressant medication, psychotherapy, and combined treatment on sexual interest/satisfaction and function in patients with chronic major depression...
  17. ncbi request reprint Differential effects of nefazodone and cognitive behavioral analysis system of psychotherapy on insomnia associated with chronic forms of major depression
    Michael E Thase
    Department of Psychiatry, University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, PA 15213 2593, USA
    J Clin Psychiatry 63:493-500. 2002
    ..As nefazodone-mediated blockade of serotonin-2 receptors may directly relieve insomnia associated with depression, we examined the more specific effects of CBASP and nefazodone, singly and in combination, on sleep disturbances...
  18. doi request reprint Factors predicting reduced antidepressant response: experience with the SNRI duloxetine in patients with major depression
    Robert H Howland
    Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Ann Clin Psychiatry 20:209-18. 2008
    ..To identify putative demographic and clinical variables that correlate with antidepressant response to the SNRI duloxetine in major depression...
  19. ncbi request reprint Self-reported depressive symptom measures: sensitivity to detecting change in a randomized, controlled trial of chronically depressed, nonpsychotic outpatients
    A John Rush
    Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390 9086, USA
    Neuropsychopharmacology 30:405-16. 2005
    ..Global patient ratings such as the PGI-I, as opposed to specific item-based ratings, provide less valid findings...
  20. ncbi request reprint Continuation treatment of chronic depression: a comparison of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination
    James H Kocsis
    Department of Psychiatry, Weill Cornell Medical College, New York, NY 10021, USA
    Psychopharmacol Bull 37:73-87. 2003
    ..COMB was associated with less symptom re-emergence during the continuation phase than either monotherapy, particularly for partial remitters...
  21. pmc Correlation between patient and clinician assessments of depression severity in the PREVENT study
    Boadie W Dunlop
    Department of Psychiatry, Emory University School of Medicine, Atlanta, GA, USA
    Psychiatry Res 177:177-83. 2010
    ..This study analyzed agreement between commonly used depression rating scales in the Prevention of Recurrent Episodes of Depression with Venlafaxine Extended Release (ER) for Two Years (PREVENT) trial...
  22. ncbi request reprint Relative antidepressant efficacy of venlafaxine and SSRIs: sex-age interactions
    Michael E Thase
    Department of Psychiatry, University of Pittsburgh Medical Center, Western Psychiatric Institute and Clinic, 3811 O Hara Street, Pittsburgh, PA 15213 2593, USA
    J Womens Health (Larchmt) 14:609-16. 2005
    ..To investigate whether differences in antidepressant efficacy are moderated by an interaction of age and gender...
  23. pmc Concordance between clinician and patient ratings as predictors of response, remission, and recurrence in major depressive disorder
    Boadie W Dunlop
    Department of Psychiatry, Emory University School of Medicine, 1256 Briarcliff Road, Building A, 3rd Floor, Atlanta, GA 30306, USA
    J Psychiatr Res 45:96-103. 2011
    ..Poor agreement between patient- and clinician-ratings of depression severity is primarily a state phenomenon, although it is trait-like for some patients...
  24. ncbi request reprint Duloxetine efficacy for major depressive disorder in male vs. female patients: data from 7 randomized, double-blind, placebo-controlled trials
    Susan G Kornstein
    Department of Psychiatry, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, USA
    J Clin Psychiatry 67:761-70. 2006
    ..Pooled data from double-blind, placebo-controlled studies were utilized to compare the efficacy of duloxetine in the treatment of major depressive disorder (MDD) in male and female patients...
  25. ncbi request reprint Symptomatic and syndromal anxiety in chronic forms of major depression: effect of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination
    Philip T Ninan
    Department of Psychiatry, Emory University School of Medicine, Atlanta, GA 30329, USA
    J Clin Psychiatry 63:434-41. 2002
    ....
  26. doi request reprint Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report
    William V Bobo
    Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN, USA
    J Affect Disord 133:467-76. 2011
    ..The clinical effects of antidepressant combinations vs. monotherapy as initial treatment for major depression with melancholic features (MDD-MF) are unknown...
  27. pmc Assessing anxious features in depressed outpatients
    Shawn M McClintock
    Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390 8898, USA
    Int J Methods Psychiatr Res 20:e69-82. 2011
    ..Both the HRSD(ANX) and IDS-C(ANX) subscales have acceptable psychometric properties and can be used to identify anxious features for clinical or research purposes...
  28. ncbi request reprint Relative antidepressant efficacy of bupropion and the selective serotonin reuptake inhibitors in major depressive disorder: gender-age interactions
    George I Papakostas
    Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Int Clin Psychopharmacol 22:226-9. 2007
    ..This finding could, however, not be replicated when improvement in anxious/somatic symptoms was defined as a continuous measure...
  29. pmc Early adverse events and attrition in selective serotonin reuptake inhibitor treatment: a suicide assessment methodology study report
    Diane Warden
    Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390 9119, USA
    J Clin Psychopharmacol 30:259-66. 2010
    ..Neither global ratings nor specific adverse effects at week 2 were related to patient attrition during SSRI treatment. Other factors seem to contribute to patient decisions about continuing with treatment...
  30. doi request reprint Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder
    Susan G Kornstein
    Department of Psychiatry and Institute for Women s Health, Virginia Commonwealth University, Richmond, VA 23209 0710, USA
    J Clin Psychiatry 71:1088-96. 2010
    ..This randomized, double-blind, placebo-controlled trial evaluated the short-term efficacy and safety of desvenlafaxine (administered as desvenlafaxine succinate) in perimenopausal and postmenopausal women with DSM-IV-defined MDD...
  31. ncbi request reprint A randomized, double-blind study of increasing or maintaining duloxetine dose in patients without remission of major depressive disorder after initial duloxetine therapy
    Susan G Kornstein
    Virginia Commonwealth University Mood Disorders Institute, Richmond, USA
    J Clin Psychiatry 69:1383-92. 2008
    ..To compare efficacy of remaining on duloxetine 60 mg to increasing to 120 mg q.d. in patients without remission of major depressive disorder (MDD) after 6 weeks at 60 mg...
  32. ncbi request reprint An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder
    Michael E Thase
    Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    CNS Spectr 14:144-54. 2009
    ..To assess the efficacy of desvenlafaxine (administered as desvenlafaxine succinate) in outpatients with major depressive disorder...
  33. ncbi request reprint Low-dose sertraline in the treatment of moderate-to-severe premenstrual syndrome: efficacy of 3 dosing strategies
    Susan G Kornstein
    Virginia Commonwealth University School of Medicine, Richmond 23298 0710, USA
    J Clin Psychiatry 67:1624-32. 2006
    ....
  34. ncbi request reprint Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression
    Michael E Thase
    Department of Psychiatry, University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, 3811 O Hara St, Pittsburgh, PA 15213, USA
    Arch Gen Psychiatry 59:233-9. 2002
    ..Although various strategies have been proposed to treat antidepressant nonresponders, little controlled research has been published that examines prospectively the use of switching to an alternate antidepressant...
  35. ncbi request reprint Chronic depression in women
    Susan G Kornstein
    Department of Psychiatry, Medical College of Virginia, Virginia Commonwealth University, Richmond 23298 0710, USA
    J Clin Psychiatry 63:602-9. 2002
    ..Young women should be screened carefully and treated vigorously to prevent the serious consequences of this condition...
  36. pmc Remission of maternal depression: relations to family functioning and youth internalizing and externalizing symptoms
    Cynthia Ewell Foster
    Department of Psychiatry, University of Michigan, Ann Arbor, MI 48105, USA
    J Clin Child Adolesc Psychol 37:714-24. 2008
    ..9% of the variance...
  37. ncbi request reprint Post hoc analysis of the efficacy and safety of desvenlafaxine 50 mg/day in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder
    Susan G Kornstein
    From the 1Institute for Women s Health, Virginia Commonwealth University, Richmond, VA 2University of Virginia, Charlottesville, VA and 3Pfizer Inc, Collegeville, PA
    Menopause 21:799-806. 2014
    ..This post hoc analysis assessed the efficacy of desvenlafaxine 50 mg/day for treating major depressive disorder in perimenopausal versus postmenopausal women enrolled in a 10-week, double-blind, placebo-controlled study...
  38. ncbi request reprint Remission as the critical outcome of depression treatment
    Michael E Thase
    Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Psychopharmacol Bull 36:12-25. 2002
    ..Obtaining a response in antidepressant therapy commonly defined in clinical trials as an improvement of erotonergic and noradrenergic neurotransmission, will increase the likelihood of remission...
  39. ncbi request reprint Why do faculty leave? Reasons for attrition of women and minority faculty from a medical school: four-year results
    Karen L Cropsey
    Department of Psychiatry, University of Alabama at Birmingham, Birmingham, Alabama 35209, USA
    J Womens Health (Larchmt) 17:1111-8. 2008
    ..The reasons why faculty in academic medical settings choose to leave their employment are not well understood. Further, it is not clear if the reasons why women and minority faculty leave differ from those of other groups...
  40. ncbi request reprint A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexual dysfunction
    Anita H Clayton
    University of Virginia, Charlottesville, VA 22903, USA
    J Clin Psychiatry 65:62-7. 2004
    ..Exploratory analyses of the association of testosterone and sexual functioning in women in the study were also performed...
  41. ncbi request reprint Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not
    Alan F Schatzberg
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305 5717, USA
    Arch Gen Psychiatry 62:513-20. 2005
    ..Although various strategies are available to manage nonresponders to an initial treatment for depression, no controlled trials address the utility of switching from an antidepressant medication to psychotherapy or vice versa...
  42. ncbi request reprint Chronic depression and comorbid personality disorders: response to sertraline versus imipramine
    James M Russell
    Department of Psychiatry and Behavioral Sciences, The University of Texas Medical Branch at Galveston, 77555, USA
    J Clin Psychiatry 64:554-61. 2003
    ..Few studies, though, have systematically examined the clinical correlates of Axis II personality disorder comorbidity or its effect on treatment response or time to response...
  43. ncbi request reprint Expert guidelines for the treatment of severe PMS, PMDD, and comorbidities: the role of SSRIs
    Meir Steiner
    Department of Psychiatry and Behavioral Neurosciences, McMaster University, Women s Health Concerns Clinic, St Joseph s Hospital, Hamilton, Ontario, Canada
    J Womens Health (Larchmt) 15:57-69. 2006
    ....
  44. ncbi request reprint Duloxetine in the treatment of major depressive disorder: comparisons of safety and tolerability in male and female patients
    Donna E Stewart
    University Health Network, University of Toronto, Ontario, Canada
    J Affect Disord 94:183-9. 2006
    ..Pooled data from double-blind, placebo-controlled studies were utilized to assess the safety and tolerability of duloxetine in the treatment of major depressive disorder (MDD) in male and female patients...
  45. ncbi request reprint Acute worsening of chronic depression during a double-blind, randomized clinical trial of antidepressant efficacy: differences by sex and menopausal status
    Anne T Harvey
    Via Christi Research, Inc, Wichita, Kan 67214, USA
    J Clin Psychiatry 68:951-8. 2007
    ....
  46. pmc Influences of hormone-based contraception on depressive symptoms in premenopausal women with major depression
    Elizabeth A Young
    Department of Psychiatry and Molecular and Behavioral Neurosciences Institute, University of Michigan, MBNI, 205 Zina Pitcher Place, Ann Arbor, MI 48109 0720, and Massachusetts General Hospital, Boston 02114, USA
    Psychoneuroendocrinology 32:843-53. 2007
    ....
  47. ncbi request reprint The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases
    Martin B Keller
    Department of Psychiatry and Human Behavior, Brown University, Providence, RI 02906, USA
    J Clin Psychiatry 68:1246-56. 2007
    ..To report second-year results from the 2-year maintenance phase of a long-term study to evaluate the efficacy and safety of venlafaxine extended release (ER) in preventing recurrence of depression...
  48. ncbi request reprint A comparison of initial duloxetine dosing strategies in patients with major depressive disorder
    Virgil G Whitmyer
    Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, Ind, USA
    J Clin Psychiatry 68:1921-30. 2007
    ..To compare the effects of starting doses of duloxetine taken with or without food on tolerability and efficacy in patients with major depressive disorder (MDD)...
  49. ncbi request reprint The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases
    Martin B Keller
    Brown University, Providence, Rhode Island 02906, USA
    Biol Psychiatry 62:1371-9. 2007
    ..We evaluated the comparative efficacy and safety of venlafaxine extended release (ER) and fluoxetine in the acute and continuation phases of treatment...
  50. ncbi request reprint Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination
    Robert M A Hirschfeld
    Department of Psychiatry and Behavioral Sciences, University of Texas Medical Branch, Galveston, Texas 77555 0188, USA
    Biol Psychiatry 51:123-33. 2002
    ..This study compared efficacy of nefazodone, psychotherapy, and their combination in improving psychosocial functioning in chronically depressed outpatients...
  51. ncbi request reprint Mental symptoms and disorders during pregnancy
    Uriel Halbreich
    Biobehavioral Research Program, State University of New York at Buffalo, Buffalo, New York, USA
    CNS Spectr 9:176. 2004
  52. doi request reprint Development and validation of the Premenstrual Symptoms Impact Survey (PMSIS): a disease-specific quality of life assessment tool
    Gene V Wallenstein
    QualityMetric Incorporated, Lincoln, Rhode Island 02865, USA
    J Womens Health (Larchmt) 17:439-50. 2008
    ..To develop and validate the Premenstrual Symptoms Impact Survey (PMSIS), a brief web-based instrument for evaluating the impact of premenstrual symptoms on health-related quality of life (HRQOL)...
  53. ncbi request reprint Gender differences in depression and response to antidepressant treatment
    Diane M E Sloan
    Clinical Services Department, CardinalHealth, Inc, 218 Colwyn Terrace, West Chester, PA 19380, USA
    Psychiatr Clin North Am 26:581-94. 2003
    ....